Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

Sr Scientist

Atilio Anzellotti, Alec Cupp and Eric Webster
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1082;
Atilio Anzellotti
1PETNET Solutions Knoxville TN United States
2PETNET Solutions Knoxville TN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alec Cupp
1PETNET Solutions Knoxville TN United States
2PETNET Solutions Knoxville TN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Webster
1PETNET Solutions Knoxville TN United States
2PETNET Solutions Knoxville TN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1082

Purpose: THE cGMP MANUFACTURING OF 68Ga-PSMA-HBED: USE OF THE AUTOMATED MODULAR-LAB “EAZY” WITH THE GALLIAPHARM 68Ge/Ga GENERATOR.

Objectives: The implementation of 68Ga-based radiopharmaceuticals in the US lags a decade compared to Europe and more recently Australia. On this work we describe the use of two components in the manufacture system for 68Ga-peptides (Generator + automated platform) that already have a Drug Master File with FDA, in order to facilitate an eventual IND. Specifically we validated the manufacture of 68Ga-PSMA-HBED including biological QC validation for Sterility and Bacterial Endotoxin Test in a commercial radiopharmacy (Hackensack, NJ) that routinely manufactures 18F-radiopharmaceuticals.

Methods: The PSMA-HBED peptide conjugate (cGMP grade), Modular-Lab eazy kits/reagents and the GalliaPharm Pharmaceutical GMP grade 68Ge/68Ga generator were purchased from Eckert & Ziegler. 68Ga was obtained from the generator using sterile ultrapure HCl 0.1 M via an automated workflow, and purified via the NaCl method (acetone-free). The Modular-Lab eazy system comprises automated control and a single-use cartridge kit with minimal manipulation. Radiochemical Identity and purity was tested via radio-TLC using a Bioscan AR-2000 equipped with WinScan software. Protocols and Summary reports for Sterility and Bacterial Endotoxin Tests were reviewed and approved internally following standard practices.

Results: Three (3) doses of sterile 68Ga-PSMA were produced in a single day by a single operator with an average activity concentration of 6.0 mCi/mL and average radiochemical purity of 97.1 %; average synthesis time was 12 min. No 68Ge breakthrough was observed based on MCA analysis. BET test for this product was validated at a dilution factor of 1:40. All key quality control requirements tested were met including Filter integrity test, Appearance, Radiochemical Identity and Purity, pH, Radionuclidic Identification, Bacterial Endotoxin and Sterility.

Conclusions: Sterile doses of 68Ga-PSMA-HBED can be produced and tested using the GalliaPharm Pharmaceutical GMP grade 68Ge/68Ga generator coupled with the Modular-Lab eazy system, and the workflow can be integrated in a commercial 18F-radio pharmacy. Research Support: None

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sr Scientist
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Sr Scientist
Atilio Anzellotti, Alec Cupp, Eric Webster
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1082;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Sr Scientist
Atilio Anzellotti, Alec Cupp, Eric Webster
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1082;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

Radiopharmacy Posters

  • Resazurin as System Suitability Indicator for Radio-TLC Analysis of [18F] Fludeoxyglucose
  • The Shortage of Approved 68Ge/68Ga Generators - Incoming Material Inspection and GMP Compliant Use of Non-Approved Generators
  • [18F]FBQ-C2 as a metabolically stable glutamine derivative for cancer imaging
Show more Radiopharmacy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire